Earnings ·
Lifeward Ltd. reported second quarter 2026 financial results showing revenue increased 16% to $6.6 million, driven by…
LFWDLifeward Ltd.
Lifeward Ltd. reported second quarter 2026 financial results showing revenue increased 16% to $6.6 million, driven by stronger sales in Europe and higher U.S. unit shipments for AlterG products. The company strengthened its balance sheet with a proforma cash balance of approximately $11 million following a strategic financing closed on July 6, 2026, which provided up to $11.2 million in growth capital. Concurrently, the Board accepted the resignation of directors Robert J. Marshall Jr., Michael Swinford, and William Mark Sigsbee effective August 13, 2026. Chief Financial Officer Almog Adar announced his departure effective September 30, 2026, to assist with a transition to a successor. Lifeward Ltd. is a diversified biomedical innovation company focused on commercialized neurorehabilitation products and a biomedical pipeline.